Cancer Epidemiology最新文献

{"title":"Years of life lost due to cancer in Ecuador","authors":"Kevin Ricardo Espinosa-Yépez","doi":"10.1016/j.canep.2024.102717","DOIUrl":"10.1016/j.canep.2024.102717","url":null,"abstract":"<div><h3>Background</h3><div>Cancer is the leading cause of death worldwide. In the Americas, it is also one of the leading causes of death. In Ecuador, studies on the burden of disease are limited and none analyze or estimate the burden of all types of cancer in a single study. Therefore, the aim of this study is to estimate the years of life lost prematurely due to cancer in Ecuador from 2014 to 2022.</div></div><div><h3>Methods</h3><div>Cross-sectional observational analysis study. The databases of general deaths from the years 2014 to 2022, population projections from 2014 to 2021 and the population census for the year 2022 of the Republic of Ecuador were used. Deaths registered with ICD-10 code C00-C96 were included as deaths from cancer. The mortality rate and years of life lost prematurely due to cancer were estimated, considering the life tables of the Coale-Demeny West model and a standard time discount of 3 % was implemented without weighting by age.</div></div><div><h3>Results</h3><div>An increase in mortality and premature years of life lost was observed in the period 2014–2019, but in 2020 a reduction in mortality was seen in several types of cancer. In 2021 and 2022 mortality increased again, reaching the maximum peak of mortality and premature years of life lost in the entire study. Approximately 1,3 million years of life lost prematurely due to cancer were estimated. The types of cancer with the greatest number of years of life lost prematurely were malignant tumors of the stomach (188.180), uterus (117.142), which include both uterine cancer and cervical cancer, and leukemia (107.440). In men, in descending order, these were tumors of the stomach (101.112), prostate (67.624) and leukemia (55.654), while in women, these were malignant tumors of the uterus (117.142), breast (100.217) and stomach (87.067).</div></div><div><h3>Conclusions</h3><div>The results of this study provide a broader basis for debate on public health policies, efficient allocation of resources, and enable monitoring of cancer and prevention strategies over time.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102717"},"PeriodicalIF":2.4,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in incidence and survival of the four most common cancers by stage at diagnosis in Cyprus: A population-based study from 2004 to 2017","authors":"Christiana A. Demetriou ,&nbsp;Constantinos Koshiaris ,&nbsp;Olivia A. Cory ,&nbsp;Constantina Constantinou ,&nbsp;Ourania Kolokotroni ,&nbsp;Yiola Marcou ,&nbsp;Demetris Papamichael ,&nbsp;Haris Charalambous ,&nbsp;Dimitrios Vomvas ,&nbsp;Anna Demetriou ,&nbsp;Vasos Scoutellas ,&nbsp;Annalisa Quattrocchi","doi":"10.1016/j.canep.2024.102704","DOIUrl":"10.1016/j.canep.2024.102704","url":null,"abstract":"<div><h3>Background</h3><div>Breast, colorectal, lung and prostate cancers are the most frequent malignancies in Cyprus. This study estimated the incidence rate and 5-year net survival (NS) trends for these cancers, by sex, age, and tumor stage at diagnosis.</div></div><div><h3>Methods</h3><div>We analyzed data from the Cyprus Cancer Registry for adults diagnosed between 2004 and 2017, with follow-up until 2019. Tumor stage was classified into localized, regional, distant and unknown categories. We estimated the annual percentage change (APC) in incidence rates using Joinpoint regression. NS was estimated using flexible parametric models, adjusting for sex, age, stage and period of diagnosis. Multiple imputation was used to address unknown cancer stage.</div></div><div><h3>Results</h3><div>During 2004–2017, the incidence significantly increased for breast and lung cancer (APC: 1.1 % and 2.6 %, respectively), mainly among the elderly (70 +). A decreasing trend was identified for prostate cancer only among individuals aged 80 +. No temporal variations were identified for colorectal cancer incidence.</div><div>A positive time trend was identified for localized breast cancer between 2006 and 2017 (APC: 2.8 %). Conversely, a significant increase was noted at more advanced stages for lung (APC_distant: 4.1 %) and prostate (APC_regional: 7.6 %) cancers.</div><div>NS improved for all cancers, ranging between 80 % and 90 % for regional and all stages of breast cancer, localized colorectal cancer, and all stages of prostate cancer, surpassing 95 % for localized breast cancer, localized and regional prostate cancer.</div></div><div><h3>Conclusion</h3><div>The study observed increased (breast and lung) or stable (colorectal and prostate) cancer incidence and substantial improvements in 5-years NS trends for all cancer types, despite differences by sex and stage. Efforts should be intensified to reduce incidence by addressing cancer risk factors, and to improve survival by implementing and increasing the uptake of screening programs.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102704"},"PeriodicalIF":2.4,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring healthy life expectancy and determinants of poor perceived health: A population-based study among a subset of rare and common cancer survivors","authors":"Eline de Heus ,&nbsp;Saskia F.A. Duijts ,&nbsp;Jan Maarten van der Zwan ,&nbsp;Carla M.L. van Herpen ,&nbsp;Matthias A.W. Merkx ,&nbsp;Mark J. Rutherford ,&nbsp;Isabelle Soerjomataram","doi":"10.1016/j.canep.2024.102706","DOIUrl":"10.1016/j.canep.2024.102706","url":null,"abstract":"<div><h3>Background</h3><div>As the survival proportions for rare cancers are on average worse than for common cancers, assessing the expected remaining life years in good health becomes highly relevant. This study aimed to estimate the healthy life expectancy (HLE) of a subset of rare and common cancer survivors, and to assess the determinants of poor perceived health in rare cancer survivors.</div></div><div><h3>Methods</h3><div>To calculate HLE, survival data from the population-based Netherlands Cancer Registry of survivors of a rare cancer (i.e., ovarian cancer, thyroid cancer, Hodgkin lymphoma, non-Hodgkin lymphoma) (n=21,376) and a common cancer (i.e., colorectal cancer (CRC)) (n=76,949) were combined with quality of life (QoL) data from the PROFILES registry on a random sample of the rare (n=1025) and common cancer (n=2400) survivors. A flexible parametric relative survival model was used to estimate life expectancy (LE) and years of life lost, and multivariate logistic regression was applied to determine factors related to reported poor perceived health.</div></div><div><h3>Results</h3><div>Patients previously diagnosed with a rare cancer had an average LE of 8–36 years and were expected to spend ≥67 % of their remaining life in good health. CRC survivors had an average LE of 10 years with approximately 65 % of their remaining life expected to spend in good health. For all cancer types, those aged ≥65 years or with stage IV had the lowest HLE. Low socioeconomic status, advanced stage, and having received radiotherapy only were important predictors of poor perceived health among rare cancer survivors.</div></div><div><h3>Conclusion</h3><div>HLE can provide meaningful perspective for patients and practitioners for all cancer types, including rare cancers. Yet, data on QoL for rare cancers should be routinely collected, as such will serve as an indicator for monitoring and improving cancer care, and for enabling HLE measurements in cancer survivors.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102706"},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal cancer survival in Mexico: Leveraging a national health insurance database","authors":"Susana Lozano-Esparza ,&nbsp;Hugo Rodrigo Sánchez-Blas ,&nbsp;Fidel David Huitzil-Meléndez ,&nbsp;Mónica Isabel Meneses-Medina ,&nbsp;Katherine Van Loon ,&nbsp;Michael B. Potter ,&nbsp;Alejandro Mohar ,&nbsp;Martin Lajous","doi":"10.1016/j.canep.2024.102698","DOIUrl":"10.1016/j.canep.2024.102698","url":null,"abstract":"<div><h3>Purpose</h3><div>We estimated the 5-year overall, age at diagnosis- and stage-specific colorectal cancer survival in patients treated through their coverage with <em>Seguro Popular</em>.</div></div><div><h3>Methods</h3><div>We conducted a retrospective study using a dataset that included 1418 colorectal cancer patients covered by <em>Seguro Popular</em> (Mexico’s public health insurance system covering 60 % of the population) between 2013 and 2016. Deaths were identified using the Epidemiologic Death Statistics Subsystem registry, with a specialized algorithm for record linkage. The Kaplan-Meier method was used to estimate overall survival curves and the proportion of patients alive at various follow-up time points. We compared survival curves across subgroups using the log-rank test.</div></div><div><h3>Results</h3><div>In this study the average age at diagnosis was 56 years with 31.9 % of patients diagnosed before the age of 50. Most cases (78.1 %) were diagnosed in advanced stages (i.e., III and IV), with nearly half of the cases originating in the rectum. The overall 5-year survival was 50 %, with higher survival (74 %) for patients with stage I-II and lower survival for those with stage III (58 %) and IV (33 %). While age at diagnosis was not associated with survival for early-stage colorectal cancer, younger patients with metastatic disease had a worse prognosis compared to older patients.</div></div><div><h3>Conclusion</h3><div>The 5-year overall colorectal cancer survival was 50 %, with variation by clinical stage. Almost 80 % of the population was diagnosed with advanced stages, underscoring the need for screening programs. Younger patients with metastatic disease exhibited a worse prognosis, highlighting the need for targeted interventions.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102698"},"PeriodicalIF":2.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rurality and pediatric cancer survival in the United States: An analysis of SEER data from 2000 to 2021","authors":"Emma Hymel ,&nbsp;Hong Li ,&nbsp;Gary L. Cochran ,&nbsp;Kendra L. Ratnapradipa ,&nbsp;Krishtee Napit ,&nbsp;Josiane Kabayundo ,&nbsp;Don W. Coulter ,&nbsp;Jenna Allison ,&nbsp;Edward S. Peters ,&nbsp;Shinobu Watanabe-Galloway","doi":"10.1016/j.canep.2024.102705","DOIUrl":"10.1016/j.canep.2024.102705","url":null,"abstract":"<div><h3>Background</h3><div>Cancer is the leading cause of death by disease among children in the United States. Residing in rural areas may impact cancer outcomes as rural areas tend to have fewer available healthcare resources. Few population-based studies have investigated rural/urban disparities in pediatric cancer outcomes. The objective of this study was to examine rural/urban differences in (1) five-year relative survival and (2) cancer-specific survival among children in the United States.</div></div><div><h3>Methods</h3><div>The study is a population-based longitudinal study using data from the Surveillance, Epidemiology, and End Results (SEER) 17 registries database (2000–2021). We included data for individuals aged 0–19 with a first primary malignant cancer diagnosed from 2000 to 2016. Rurality was measured by Rural-Urban Continuum Codes (RUCCs). Five-year relative survival rates, Kaplan-Meier curves, and Cox regression analysis were used to determine the differences in pediatric cancer survivorship between rural and urban areas.</div></div><div><h3>Results</h3><div>Both five-year relative survival rates and log-rank tests of survival probabilities over time by rurality showed no statistically significant difference between individuals living in urban versus rural counties. However, after adjusting for age, sex, race/ethnicity, cancer type, median household income, and region, children diagnosed in rural counties had a 9 % higher risk of death compared to children diagnosed in urban counties (95 % CI 1.02–1.17), with the highest increased risk observed for children with retinoblastoma (aHR: 6.12, 95 % CI 2.01–18.59). A higher increased risk of death was observed for children living in the most rural counties (aHR: 1.18, 95 % CI 1.07–1.32).</div></div><div><h3>Conclusion</h3><div>In this study, residing in rural areas was associated with an increased risk of death from pediatric cancer, especially for children residing in rural areas not adjacent to urban areas. Our findings warrant further investigation to determine the rural/urban disparities in pediatric cancer outcomes and to develop interventions to deliver high-quality cancer care to rural children.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"94 ","pages":"Article 102705"},"PeriodicalIF":2.4,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN","authors":"Jialin Zhou ,&nbsp;Ying Xu ,&nbsp;Jianmin Liu ,&nbsp;Lili Feng ,&nbsp;Jinming Yu ,&nbsp;Dawei Chen","doi":"10.1016/j.canep.2024.102693","DOIUrl":"10.1016/j.canep.2024.102693","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050.</div></div><div><h3>Methods</h3><div>In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections.</div></div><div><h3>Results</h3><div>In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050.</div></div><div><h3>Conclusions</h3><div>Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102693"},"PeriodicalIF":2.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in age and stage-specific incidence of colorectal cancer in Saudi Arabia: A registry-based cohort study between 1997 and 2017","authors":"Norah Alsadhan ,&nbsp;Mar Pujades-Rodriguez ,&nbsp;Sultana A. Alhurishi ,&nbsp;Farag Shuweihdi ,&nbsp;Cathy Brennan ,&nbsp;Robert M. West","doi":"10.1016/j.canep.2024.102699","DOIUrl":"10.1016/j.canep.2024.102699","url":null,"abstract":"<div><h3>Background</h3><div>In Saudi Arabia, colorectal cancer (CRC) is the most common cancer in men and the third in women, posing a significant health burden. A comprehensive report of CRC incidence rates and trends in Saudi Arabia is lacking. This study aims to examine trends in CRC incidence among the Saudi population.</div></div><div><h3>Methods</h3><div>We used data from the Saudi Cancer Registry to examine CRC age-specific incidence rates (ASIR) and age-standardized incidence rates (ASR) between 1997 and 2017. Joinpoint regression analysis was used to determine the magnitude and direction of observed trends stratified by age, sex, and CRC stage at diagnosis. Trends were measured using the annual percentage change (APC) and the average annual percentage change (AAPC) in CRC incidence rates.</div></div><div><h3>Results</h3><div>In total, 19,463 new CRC cases were identified during the study period. Since 1997, ASR for CRC has steadily increased in men and women overall, irrespective of disease stages. The ASIR increased across all age groups and was more pronounced in older patients. Women aged 40–49 had a higher increase in incidence than men (AAPC= 5.3 % vs.4.7 %). Males aged 70–79 had an AAPC of 10.2 %, twice that of females (AAPC= 4.9 %). A consistent rise in ASIR was observed across all CRC stages and age groups in males and females. In recent years, males under 50 had a higher APC for distant CRC than females, while females aged 50–74 experienced a steeper increase in distant CRC than males.</div></div><div><h3>Conclusion</h3><div>We report a marked increase in the incidence of CRC over time in Saudi Arabia, affecting men and women across all age groups and disease stages at diagnosis. Our findings underscore the need to identify underlying risk factors and to develop and implement effective prevention policies and strategies, including screening programs to facilitate early detection and treatment.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102699"},"PeriodicalIF":2.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer in the Grand Libreville, Gabon (2013–2017)","authors":"Mahine Ivanga ,&nbsp;D. Maxwell Parkin ,&nbsp;Angela Filankembo Kava ,&nbsp;Christian Nziengui Tirogo ,&nbsp;Paul Nzamba Bissielou ,&nbsp;Alex Kabena ,&nbsp;Corinne Engohan Aloghe ,&nbsp;Rose Revignet ,&nbsp;Alexis Parente ,&nbsp;Veronique Blanquet ,&nbsp;Edgard Brice Ngoungou ,&nbsp;Ismael Herve Koumakpayi ,&nbsp;Ernest Belembaogo","doi":"10.1016/j.canep.2024.102695","DOIUrl":"10.1016/j.canep.2024.102695","url":null,"abstract":"<div><h3>Background</h3><div>The burden of cancer is expected to nearly double in sub-Saharan Africa over the next 20 years. In Gabon, the primary population-based cancer registry to be established is located in the Grand Libreville. This study presents cancer incidence rates covering the first 5-year period of registration in this region.</div></div><div><h3>Patients and methods</h3><div>1,549 cancer cases were recorded among residents of the Grand Libreville between 2013 and 2017, 955 (61.6 %) women and 594 (38.3 %) males.</div></div><div><h3>Results</h3><div>The age standardized incidence rates (ASR) for all sites were 73.3 per 10⁵ in females and 47.7 per 10⁵ in males, rather similar from those observed in neighbouring countries of central Africa. Breast (ASR 19.0 per 10⁵) and cervical cancers (ASR 16.3 per 10⁵) accounted for half of female cancers. Prostate (ASR 12.0 per 10⁵), liver (ASR 5.1 per 10⁵) and colorectal cancers (ASR of 5.0 per 10⁵) accounted for 41.1 % of male cancers.</div></div><div><h3>Conclusion</h3><div>Breast and prostate cancers ranked first in females and males, respectively, even if the incidences appear much lower in comparison with other regional cancer registries rates, implying they may be underestimated. Cancers of the digestive organs were markedly more frequent in men than women, especially for liver, colorectal (and anus) and the mouth and pharynx. The incidence rates of these latter cancers are relatively similar to those of other registries of the central African region. These results may be of importance for implementing more adapted strategies in the battle against cancer.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102695"},"PeriodicalIF":2.4,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital as a site of death of cancer patients in Italy: A registry-based analysis and time trends","authors":"Gianmauro Numico ,&nbsp;Roberto Ippoliti ,&nbsp;Andrea Antonuzzo ,&nbsp;Lorenza Palmero ,&nbsp;Paolo Bossi","doi":"10.1016/j.canep.2024.102702","DOIUrl":"10.1016/j.canep.2024.102702","url":null,"abstract":"<div><h3>Background</h3><div>Place of death is relevant both for individuals and for the society. Home is universally considered the optimal place of death while dying in hospital may be a signal of inappropriate end-of-life care. We aimed at studying the place of death of patients with cancer in Italy in a five-year period.</div></div><div><h3>Patients and methods</h3><div>The death-certificate database published by the Italian National Institute of Statistics (ISTAT) was analysed, searching the place of death and the main disease related to death. Data from 2015 to 2019 were used, to exclude the influence of the COVID pandemic. Cancer, “cognitive impairment and Alzheimer’s disease” (CIAD) and “cardiovascular and cerebrovascular diseases” (CCD) were the examined diseases. The place of death was categorized as “acute care hospital”, “hospice” or “other long-term care (LTC) structures” and “home”. We implemented an ordinary linear regression model to verify whether there was a statistically significant variation across the selected time (i), and whether a substitution effect among sites of death could be hypothesized (ii).</div></div><div><h3>Results</h3><div>Data on 769,517 deaths were retrieved. In 2019 35.39 % patients with cancer died in hospital, 39.57 % died at home and 20.06 % died in hospice or in other LTC structures. In the examined period, death at home decreased by 3.09 % (95 % C.I. −3.18 - −2.99; p&lt;0.01); death in hospice and long-term structures increased by 2.71 % (95 % C.I. 2.66 – 2.76; p&lt;0.01); death in hospital increased by 0.3 % (95 % C.I. 0.23 – 0.36; p&lt;0.01). For patients with CIAD, death in hospital increased by 0.98 % (95 % C.I. 0.80 – 1.17; p&lt;001) and for patients with CCD decreased by 1.43 % (95 % I.C. −1.47 – −1.39; p&lt;0.01). Death at home decreased in both diseases.</div></div><div><h3>Conclusions</h3><div>More than one-third of cancer patients die in acute care hospitals and this percentage is slightly increasing in the analysed period. Mortality at home decreased in all the examined diseases. Dying at home is being progressively less frequent, while hospitals continue to represent a frequent place of death.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102702"},"PeriodicalIF":2.4,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States","authors":"Ray M. Merrill","doi":"10.1016/j.canep.2024.102700","DOIUrl":"10.1016/j.canep.2024.102700","url":null,"abstract":"<div><h3>Background</h3><div>Changes in US prostate-specific antigen (PSA) screening guidelines have impacted prostate cancer (PCa) incidence rates and trends. This study shows corresponding changes in PCa incidence rates and describes treatment patterns by tumor stage, age, and race/ethnicity.</div></div><div><h3>Methods</h3><div>Analyses were based on 777,152 cases diagnosed in 17 population-based tumor registries in the SEER Program of the US National Cancer Institute, 2007–2021. Rates were age adjusted and trends assessed using annual percent change and joinpoint regression.</div></div><div><h3>Results</h3><div>PCa age-adjusted incidence rates (per 100,000) fell from 165.8 in 2007 to 101 in 2014 (APC=-6.51, p&lt;0.05) and then rose to 121.2 in 2021 (APC=1.87, p&lt; 0.05). The significant fall and rise in rates appeared in ages 55–69 and ≥70, all racial/ethnic groups (except in Hispanics during 2014–2021), and in local/regional stage. PCa incidence rates by tumor stage, age, and race/ethnicity were presented and discussed. A few PCa cases were identified through autopsy or death certificate among the racial/ethnic groups (0.68 %-1.37 %). Unstaged cases identified through sources other than autopsy or death certificate significantly varied by race/ethnicity, ranging from 4.13 % for non-Hispanic (NH) Whites to 9.5 % for Hispanic (Chi-square p &lt;.0001). In 2017–2021, surgery occurred in 33 % of cases (primarily in local/regional cases, inversely associated with age), radiation in 30 % of cases (increasing with age in local/regional stage cases and decreasing with age in distant stage cases), and chemotherapy in 2 % of cases (&lt;1 % in local/regional stage cases and 9 %-38 % for age groups in distant stage cases). Several racial/ethnic differences in treatment exist, such as NH Blacks (vs. NH Whites) with local/regional disease were significantly less likely to receive surgery and more likely to receive radiation.</div></div><div><h3>Conclusions</h3><div>Understanding trends and patterns of PCa rates and treatment among patients by tumor stage, age, and race/ethnicity can guide public health planning in relation to screening and treatment.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102700"},"PeriodicalIF":2.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}